Table 1.
Demographics
| All participants with CH | Triptan users (injections or nasal spray) | Triptan non-users | Triptan tablet users (exclusively) | |
|---|---|---|---|---|
| Number of individuals | 893 | 692 | 160 | 41 |
| Age (years) | 50.3 ± 14.3 | 49.4 ± 13.9 | 53.5 ± 15.2 | 51.9 ± 16.6 |
| Age at onset (years)a | 31.8 ± 13.4 | 31.0 ± 13.0 | 35.1 ± 14.7 | 34.4 ± 14.8 |
| Male % (n) | 65.6% (586) | 67.8% (469) | 58.8% (94) | 56.1% (23) |
| Chronic % (n)b | 12.5% (111) | 12.3% (85) | 12.1% (19) | 17.1% (7) |
| Heredity % (n)c | 12.4% (107) | 13.1% (88) | 8.3% (13) | 15.4% (6) |
Numerical data presented as mean ± standard deviation. Triptan users regularly use one or more of the following: sumatriptan injections, sumatriptan nasal spray, or zolmitriptan nasal spray. Triptan tablet users exclusively use triptans in the form of tablets: rizatriptan tablet, sumatriptan tablet, zolmitriptan tablet, and eletriptan tablet. Triptan non-users do not use triptans in any form. Percentages do not include missing data
CH cluster headache
aAge at onset (n =803)
bInfo on chronic or episodic subtype from n = 888
cInfo on heredity from n = 865